Loxonin relieves pain and inflammation after operation, trauma and tooth extraction.

For a single administration, 60-120 mg is orally given.

The dosages should be adjusted according to age and symptoms.

Loxoprofen sodium is sodium 2-[p-(2-oxocyclopentylmethyl)phenyl] propionate dihydrate, with a molecular formula of C15H17NaO3·2H2O.

Pharmacology: Sodium loxoprofen, synthesized and developed by Sankyo Co. Ltd., is a new nonsteroidal analgesic and anti-inflammatory drug in the phenylpropionic acid group. It is rapidly absorbed from the gastrointestinal tract and shows excellent analgesic and anti-inflammatory effects, while this drug is characterized by its relatively lower toxicity to the gastrointestinal tract than other nonsteroidal analgesic and anti-inflammatory drugs because it is a prodrug showing effects after conversion to active compounds in the body.

Loxonin has excellent analgesic and anti-inflammatory effects, and its analgesic effect is specifically powerful. Loxonin has pharmacological characteristics eg, a relatively lower toxicity to the gastrointestinal tract than other nonsteroidal analgesic and anti-inflammatory drugs because it is the prodrug showing the effect after absorption from the gastrointestinal tract and conversion to active metabolites. The mode of action of Loxonin is prostaglandin biosynthesis inhibition and its site of action is cyclooxygenase.

Pharmacokinetics: After oral administration, Loxonin is rapidly absorbed from the digestive tract in the unchanged form causing weak irritation to the stomach mucosa, and then rapidly converted to an active metabolite, the trans-alcohol form (in SRS configuration) which potently inhibits prostaglandin biosynthesis.

Urinary excretion of Loxonin is rapid, and most amount of the drug administered is excreted in the unchanged form or in the glucuronic acid conjugated trans-OH form. About 50% of the dose is excreted in the urine within 8 hrs after administration.